Regentis Biomaterials Ltd. Ordinary Shares (RGNT)
Healthcare › Medical Instruments & Supplies
Price History
Feb 27, 2026 — Mar 28, 2026Investment Snapshot
- P/B of 3.44 — trading above book value
- Piotroski F-Score 1/9 — signs of financial weakness
- Loss-making — negative ROE of -287.7%
Regentis Biomaterials Ltd. Ordinary Shares (RGNT) is a Healthcare company operating in Medical Instruments & Supplies, listed on the AMEX , with a market capitalisation of $16 million . Key value metrics: P/B ratio 3.44, Piotroski F-Score 1 out of 9 .
Value Score
Key Metrics
Revenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Regentis Biomaterials Ltd. Ordinary Shares — Fundamental Analysis Summary
On financial health, RGNT shows a weak Piotroski F-Score of 1/9, a signal of deteriorating financial health, and negative return on equity of -287.7% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.25.
StockPik's composite Value Score for RGNT is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RGNT shows earnings declining at 384%.